Medarex/Bristol Plan To File Ipilimumab For Metastatic Melanoma Despite Phase II Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.
You may also be interested in...
Weak Result Stops Pfizer’s Tremelimumab Phase III Trial
Failure casts doubt on Bristol/Medarex’s CTLA-4 inhibitor ipilimumab, analysts say.
Weak Result Stops Pfizer’s Tremelimumab Phase III Trial
Failure casts doubt on Bristol/Medarex’s CTLA-4 inhibitor ipilimumab, analysts say.
Genasense Phase III Melanoma Trial Gets Green Light
Genta aims for first approval in tough disease, CEO tells “The Pink Sheet” DAILY.